Blood Rheology After Allogeneic Hematopoietic Stem Cell Transplantation or Gene Therapy in Sickle Cell Disease

Abstract

Allogeneic hematopoietic cell transplantation (HCT) and autologous hematopoietic stem cell–based gene therapies are potentially curative for sickle cell disease (SCD). Although most patients experience resolution of overt clinical symptoms associated with SCD with donor-dominant myeloid chimerism after undergoing HCT or the induction of a substantial amount of alternative hemoglobin after gene therapy, whether the underlying subclinical physiology is normalized in these individuals is unknown. One approach to evaluating the underlying physiology is to characterize the blood rheology of patients after they receive these therapies